Short answer
Oncology Institute, Inc. (TOI) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Item 2.02 furnishes Exhibit 99.1 without Section 18 Exchange Act filing liability.
Oncology Institute, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Item 2.02 furnishes Exhibit 99.1 without Section 18 Exchange Act filing liability
- Investor-relevant results and financial details are contained in Exhibit 99.1, not the provided text
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $161.3M, up 34.6%, led by Specialty Pharmacy revenue growth of 58%
- Adjusted EBITDA turned positive at $229K versus $(4.1)M, signaling progress toward profitability
- Full-year revenue guidance raised to $650–$670M and gross profit to $105–$110M
- California exclusivity added approximately 230,000 capitated lives, supporting future recurring revenue growth
- Cash $41.1M versus $79.9M long-term debt, leaving liquidity and leverage key investor watchpoints
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Oncology Institute, Inc. 8-K filings
Get the next TOI 8-K as it lands
Follow TOI for push alerts, or ask the research agent what this filing means.